相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies
A. B. Gottlieb et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients
David Hagg et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20
N. Ponnambath et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2016)
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
Bruce E. Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Factors associated with the prescription of traditional'' or biological'' systemic treatment in psoriasis
Stefano Tabolli et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men
David Hagg et al.
PLOS ONE (2013)
Psoriasis Severity and the Prevalence of Major Medical Comorbidity A Population-Based Study
Howa Yeung et al.
JAMA DERMATOLOGY (2013)
Risk of myocardial infarction in patients with psoriasis
Joel M. Gelfand et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis
J Schmitt et al.
DERMATOLOGY (2005)
Facial psoriasis: Comparison of patients with and without facial involvement
JY Park et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
分享论文
